Up to $70m · Debt · Healthtech · Lausanne, Switzerland
DEXTER robotic surgery system. Credit: Distalmotion.
Lausanne-based Distalmotion has entered into a senior secured term loan facility of up to $70m with Perceptive Advisors. The company says the financing will support further US expansion in ambulatory surgery centres and continued development of its DEXTER robotic surgery system and instrument portfolio.
The qualifier matters: this is a facility of up to $70m, not evidence that the entire amount was funded at signing. Distalmotion has not disclosed the amount drawn at close, pricing, maturity or drawdown conditions.
A robot designed around outpatient constraints
DEXTER is a soft-tissue surgical robot built around a small, mobile footprint rather than a permanently installed operating-room setup. Its surgeon console remains in the sterile field, while patient carts and fully wristed instruments support minimally invasive procedures. Distalmotion argues that the format lets ambulatory surgery centres add robotics without rebuilding rooms or adopting the infrastructure associated with larger hospital platforms.
The regulatory scope has widened during 2026. FDA documentation covers additional gynaecology indications, and a later clearance added ventral hernia repair. Distalmotion now describes DEXTER as cleared for four high-volume outpatient procedure groups: cholecystectomy, inguinal hernia repair, ventral hernia repair and hysterectomy, among other indications. The company said in June that more than 4,000 patients had been treated with the system.
That breadth creates a commercial mechanism specific to outpatient surgery. An ASC can justify a capital platform more easily when several service lines can use it, rooms do not need major modification and the system can move between theatres. More eligible procedures can increase utilisation, while the associated single-use instruments create continuing demand after installation. The company has not disclosed pricing or customer economics, so the strength of that model will depend on procedure volume, training time and reliable support at each site.
Debt puts the next proof point on utilisation
The facility follows a $150m Series G announced in November 2025 and a strategic investment from Johnson & Johnson Innovation in January 2026. Adding secured debt gives Distalmotion more capital for commercial expansion without presenting this financing as another equity round, but it also places greater weight on execution because the repayment terms sit alongside a costly US rollout.
Medical-device reporting notes that the company has been expanding US clearances and commercial adoption across outpatient settings. The next proof point is not another regulatory milestone alone. Distalmotion must show that centres can install DEXTER, train teams and run enough cases across multiple procedures to make the platform operationally useful. If utilisation grows within existing rooms and workflows, the mobile design can support repeatable site expansion. If deployments remain bespoke or case volumes stay narrow, the facility may extend the rollout without yet proving its economics.
